Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial

What Was Tested

Researchers studied Cyanocobalamin (Vitamin B12) in this randomized controlled trial publication.

This study was conducted to investigate and compare the effects of add-on folic acid and vitamin B12 supplementation on glycaemic control, insulin resistance and serum lipid profile in subjects with type 2 diabetes mellitus.

Who Took Part

The abstract describes 80 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults.

The patients were followed up after 8 weeks.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Cyanocobalamin (Vitamin B12) and who got the comparison, which limits bias.

Everyone knew when Cyanocobalamin (Vitamin B12) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The methods mention a period of 8 weeks.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Dietary Supplements, Folic Acid, Glycemic Control, Insulin Resistance, Lipids and Vitamin B 12.

The authors tagged it with the keywords Type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized and open-label study of Cyanocobalamin (Vitamin B12) in 80 patients over 8 weeks.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Complementary therapies in medicine), a journal based in Scotland.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.